Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant

International Journal of Pharmaceutics

Volumn 338, Issue 1-2, 2007, Pages 87-93

  Takatsuka, Shinya ^a   Morita, Takahiro ^a   Horikiri, Yuji ^a   Yamahara, Hiroshi ^a   Saji, Hideo ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Combination; Mucolytic agent; Mucosal; Non ionic surfactant; Poorly absorbed hydrophilic compounds

Indexed keywords

ACETYLCYSTEINE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; OCTOXINOL; SALCATONIN;

ANIMAL EXPERIMENT; ARTICLE; COLON ABSORPTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HYDROPHILICITY; LUNG PARENCHYMA; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT;

ABSORPTION; ACETYLCYSTEINE; ANIMALS; INTESTINAL ABSORPTION; LUNG; MALE; MUCOUS MEMBRANE; NASAL MUCOSA; OCTOXYNOL; RATS; RATS, WISTAR;

EID: 34248673162     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.027     Document Type: Article

References (23)

1. Agu R.U., Ugwoke M.I., Armand M., Kinget R., and Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2 (2001) 198-209
2. Atuma C., Strugala V., Allen A., and Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280 (2001) G922-G929
3. Byron P.R., and Patton J.S. Drug delivery via the respiratory tract. J. Aerosol Med. 7 (1994) 49-75
4. Edwards C. Physiology of the colorectal barrier. Adv. Drug Deliv. Rev. 28 (1997) 173-190
5. Enna S.J., and Schanker L.S. Absorption of saccharides and urea from the rat lung. Am. J. Physiol. 222 (1972) 409-414
6. Hamman J.H., Enslin G.M., and Kotzé A.F. Oral delivery of peptide drugs. Biodrugs 19 (2005) 165-177
7. Haupt S., and Rubinstein A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 499-551
8. Hirai S., Yashiki T., Matsuzawa H., and Mima H. Absorption of drugs from the nasal mucosa of rat. Int. J. Pharm. 7 (1981) 317-325
9. Hosoya K., Kubo H., Natsume H., Sugibayashi K., Morimoto Y., and Yamashita S. The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits. Biopharm. Drug Dispos. 14 (1993) 685-696
10. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Rel. 94 (2004) 15-24
11. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control. Rel. 87 (2003) 187-198
12. Kagatani S., Shinoda T., Fukuni M., Ohmura T., Hasumi S., and Sonobe T. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res. 13 (1996) 739-743
13. Kobayashi S., Kondo S., and Juni K. Critical factors on pulmonary absorption of peptides and proteins (diffusional barrier and metabolic barrier). Eur. J. Pharm. Sci. 4 (1996) 367-372
14. Livingstone C.R., Andrews M.A., Jenkins S.M., and Marriott C. Model systems for the evaluation of mucolytic drugs: acethylcysteine and S-carboxymethylcysteine. J. Pharm. Pharmacol. 42 (1990) 73-78
15. Mahato R.I., Narang A.S., Thoma L., and Miller D.D. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20 (2003) 153-214
16. Patton J.S., Trinchero P., and Platz R.M. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormone. J. Control. Rel. 28 (1994) 79-85
17. Sinswat P., and Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int. J. Pharm. 257 (2003) 15-22
18. Struck M.M. Biopharmaceutical R&D success rates and development times: a new analysis provides benchmarks for the future. Bio/Technology 12 (1994) 674-677
19. Takatsuka S., Kitazawa T., Morita T., Horikiri Y., and Yoshino H. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur. J. Pharm. Biopharm. 62 (2006) 52-58
20. Takatsuka S., Morita T., Koguchi A., Horikiri Y., and Yoshino H. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int. J. Pharm. 316 (2006) 124-130
21. Ugwoke M.I., Agu R.U., Verbeke N., and Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57 (2005) 1640-1665
22. Walsh G. Biopharmaceutical benchmarks-2003. Nat. Biotechnol. 21 (2003) 865-870
23. 1.7]-eel calcitonin from various mucosal administration sites. J. Control. Rel. 76 (2001) 363-374